Purdue Pharma L.P.
Case Number:
7:19-bk-23649
Court:
Nature of Suit:
Firms
- Blitman & King
- Bielli & Klauder
- Doster Ullom
- Tarter Krinsky
- Teitelbaum Law Group
- Simmons Hanly
- Stevens & Lee
- Godfrey & Kahn
- Pillsbury Winthrop
- Gilbert LLP
- Himes Petrarca
- Lowe Stein
- Skadden Arps
- Seyfarth Shaw
- Wachtell Lipton
- Archer & Greiner
- Porter Hedges
- Gage Spencer & Fleming
- ArentFox Schiff
- Dentons
- Kirkland & Ellis
- Consovoy McCarthy
- Kobre & Kim
- Morgan Lewis
- Gertz & Rosen
- Porteous Hainkel
- Crowell & Moring
- Troutman
- Andrews & Thornton
- Bentley & Bruning
- ASK LLP
- Willkie Farr
- Joseph Hage
- Potter Anderson
- Spangenberg Shibley
- Cuneo Gilbert
- White & Case
- Motley Rice
- Mintz Levin
- WestLoop Law
- Arnold & Porter
- Miller Nash LLP
- McDermott Will & Schulte
- McGrail & Bensinger
- Taft Stettinius
- Cronin Fried
- Loeb & Loeb
- Cleary Gottlieb
- Jones Day
- Robins Kaplan
- MoloLamken
- Faegre Drinker
- Duane Morris
- Foley & Lardner
- Reed Smith
- Slevin & Hart
- Doshi Legal Group
- Hogan Lovells
- Shook Hardy
- Goodwin Procter
- Schenck Price
- Pachulski Stang
- Lerner Arnold
- Bialson Bergen
- Martin S. Rapaport
- Brown Rudnick
- Marino Tortorella
- Saul Ewing
- Davis Polk
- BatesCarey
- Burke Warren
- King & Spalding
- Wilk Auslander
- Stutzman Bromberg
- WilmerHale
- Phillips Lytle
- Brown & Connery
- Hagens Berman
- Napoli Shkolnik
- Marcus & Shapira
- Quinn Emanuel
- Squire Patton
- Shafferman & Feldman
- Ballard Spahr
- Hughes Socol
- Keller Rohrback
- O'Melveny & Myers
- Blank Rome
- Keller Postman
- Kleinberg Kaplan
- Katsky Korins
- Clifford Law Offices
- Barack Ferrazzano
- Terrell Hogan
- Sherrard Roe
- Levenfeld Pearlstein
- Rothstein Mandell
- Debevoise & Plimpton
- MacElree Harvey
- Pashman Stein
- Hurwitz Fine
- Pullman & Comley
- Mehri & Skalet
- Tate Law Group LLC
- Klehr Harrison
- Frost Brown
- Lowey Dannenberg
- Williams Mullen
- UB Greensfelder
- Waldrep Wall
- Dechert LLP
- Ifrah Law
- Seward & Kissel
- Simpson Thacher & Bartlett LLP
- Calfee Halter
- White Coleman & Associates
- Caplin & Drysdale
- Miller Shah
- O'Brien Belland
- Binder & Schwartz
- Alston & Bird
- Akin Gump
- Carter Ledyard
- Shipman & Goodwin
- McElroy Deutsch
- Henrichsen Law Group
- Jenner & Block
- Haug Partners
- HSF Kramer
- Hobbs Straus
- Latham & Watkins
- Mayer Brown
- Milbank LLP
Companies
- Teamsters Local 456
- Henry Schein Inc.
- Hikma Pharmaceuticals PLC
- Walmart Inc.
- McKesson Corp.
- Otis Worldwide Corp.
- Impax Laboratories, Inc.
- Johnson & Johnson
- Kodiak Area Native Association
- Ranbaxy
- Tucson Medical Center
- PRA Health Sciences Inc.
- Ascent Pharmaceuticals Inc.
- Blue Cross Blue Shield Association
- Aleutian Pribilof Islands Association Inc.
- Collegium Pharmaceutical Inc.
- Endo International PLC
- Omnicare Inc.
- Giant Eagle Inc.
- Bausch Health Cos. Inc.
- Province LLC
- United Parcel Service Inc.
- Sandoz International GmbH
- Avrio Health LP
- Nardello & Co. LLC
- Cencora Inc.
- Express Scripts Holding Co.
- Hain Capital Group LLC
- CVS Health Corp.
- KVK Tech Inc.
- Amneal Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Ltd.
- Loblaw Cos.
- TR Capital Management LLC
- The Cigna Group
- Ironshore Inc.
- Noramco Inc.
- Alaska Native Tribal Health Consortium
- Anda Inc.
- AlixPartners LLP
- AXA XL Ltd.
- Allergan PLC
- Purdue Pharma LP
- United Food & Commercial Workers International Union
- Viatris Inc.
- FTI Consulting Inc.
- ASM Capital LP
- SAP AG
- Apria Healthcare Group
- Cardinal Health Inc.
- Liberty Mutual Insurance Group
- Bristol-Myers Squibb Co.
- Arcadia Consumer Healthcare
- International Union Of Operating Engineers
- DuPont de Nemours Inc.
- Old Republic Insurance Co.
- Oracle Corp.
- Thermo Fisher Scientific Inc.
- Verita Global LLC
- Houlihan Lokey Inc.
- American Federation of Labor & Congress of Industrial Organizations
- Jefferies Financial Group Inc.
- Teva Pharmaceutical Industries Ltd.
Government Agencies
- Seldovia Village Tribe
- Pension Benefit Guaranty Corp.
- Missouri Department of Revenue
- Pala Band of Mission Indians
- U.S. District Court for the District of Columbia
- Town of Ramapo, New York
- City of Bayonne, New Jersey
- Commonwealth of Massachusetts
- State of Nevada
- Washington State Department of Revenue
- Nez Perce Tribe
- Port Gamble S'Klallam Tribe
- Borough of Paramus, New Jersey
- Jamestown S'Klallam Tribe
- Northwestern Band of the Shoshone Nation
- St. Regis Mohawk Tribe
- Town of Babylon, New York
- Town of Brookhaven, New York
- New York Department of Financial Services
- Town of Hempstead, New York
- State of Indiana
- Hopi Tribe
- Tennessee Attorney General's Office
- Suquamish Tribe
- Ohio Attorney General's Office
Sectors & Industries:
-
January 20, 2021
Purdue Committees Get OK To Join Insurance Suits
A New York bankruptcy judge Wednesday gave Purdue Pharma and two of its creditor committees permission to file joint actions seeking coverage from the drugmaker's insurance carriers as the company said it is close to filing a Chapter 11 plan.
-
January 19, 2021
Purdue Insurer Says Committees Can't Bring Coverage Suits
An insurance carrier for bankrupt opioid maker Purdue Pharma has asked a New York bankruptcy judge to deny the company's request to share the right to file insurance suits with a pair of its creditor committees, saying the claims would be barred by state law.
-
December 21, 2020
CORRECTED: Sacklers Saw Litigation Threat As Early As 2007, Creditors Say
Members of the Sackler family, which owns OxyContin maker Purdue Pharma LP, discussed that opioid litigation could be a threat to the family and company’s finances as early as 2007, according to filings in New York bankruptcy court. Correction: A prior version of this story inaccurately framed the description of bankruptcy with respect to Purdue and the Sacklers. The error has been corrected.
-
November 17, 2020
Purdue Pharma Gets Court Approval For $8B Deal With Feds
A New York bankruptcy Judge on Tuesday approved Purdue Pharma's $8 billion settlement of federal felony charges stemming from its OxyContin sales and said Purdue's former owning family can pay $225 million in fines without violating court orders.
-
November 16, 2020
Feds Say $225M Sackler Fine To Go To Medicare, Medicaid
The U.S. attorney's office has told a New York bankruptcy judge that nearly all of the $225 million settlement of federal opioid litigation against the former owning family of Purdue Pharma will go into the general Medicare and Medicaid budget.
-
November 12, 2020
States Say $8.3B Purdue Opioid Deal Flouts Bankruptcy Rules
A group of states on Tuesday voiced opposition to Purdue Pharma LP's $8 billion OxyContin settlement with the federal government, saying that the plan puts the bankruptcy case parties in a "straitjacket."
-
October 28, 2020
Fight Over Sackler Deal On Hold For Purdue Ch. 11 Plan Talks
Whether Purdue Pharma's unsecured creditors can stop the Sackler family from using corporate funds to pay a $225 million fine that's part of the $8 billion OxyContin settlement with the federal government will wait for parties to negotiate over the company's Ch. 11 plan, a New York bankruptcy judge said Wednesday.
-
October 27, 2020
Purdue Creditors Object To Sackler Part Of $8B DOJ Deal
Creditors of drugmaker Purdue Pharma on Tuesday asked a New York bankruptcy judge to bar the use of corporate funds to pay the $225 million that members of its former owning family owe the government under the $8 billion OxyContin sale settlement announced last week.
-
October 21, 2020
Sackler Factor Could Sink Purdue's $8B Opioid Deal With DOJ
While the $8 billion criminal and civil settlement OxyContin maker Purdue Pharma made with the federal government resolves the Chapter 11 claim from its single largest creditor, it could draw fatal opposition in bankruptcy court for failing to address the potential liability related to the Sackler family's ownership of the company.
-
October 16, 2020
Purdue, Sacklers Say Atty-Client Privilege Shields Documents
Purdue Pharma and members of its former owning family are asking a New York bankruptcy judge to reject new document requests by the unsecured creditors committee in its Chapter 11 case, saying the committee is seeking privileged communications without justification.